Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.

Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M, Chang P, Francis GS.

Neurology. 2005 Sep 27;65(6):802-6. Epub 2005 Aug 10. Review.

PMID:
16093457
2.

Multiple sclerosis: management issues during pregnancy.

Ferrero S, Pretta S, Ragni N.

Eur J Obstet Gynecol Reprod Biol. 2004 Jul 15;115(1):3-9. Review.

PMID:
15223156
3.

The importance of maintaining effective therapy in multiple sclerosis.

Durelli L, Clerico M.

J Neurol. 2005 Sep;252 Suppl 3:iii38-iii43. Review.

PMID:
16170500
4.

Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome.

Henderson J, Gray R, Brocklehurst P.

BJOG. 2007 Mar;114(3):243-52. Epub 2007 Jan 12. Review. Erratum in: BJOG. 2007 Jul;114(7):914-5.

5.

The Rebif new formulation story: it's not trials and error.

Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M.

Drugs R D. 2007;8(6):335-48. Review.

PMID:
17963425
6.

Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.

Arnason BG.

J Neurol. 2005 Sep;252 Suppl 3:iii28-iii33. Review.

PMID:
16170497
7.

Early treatment and dose optimisation BENEFIT and BEYOND.

Hartung HP.

J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50. Review.

PMID:
16170501
8.

Spontaneous abortions, stillbirths and birth defects in epidemiological search for risk indicators.

Heinonen OP.

Dev Toxicol Environ Sci. 1986;12:63-76. Review. No abstract available.

PMID:
3104005
9.
10.

Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.

Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J.

Drug Saf. 2007;30(3):247-64. Review.

PMID:
17343431
11.
12.

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

Tremlett HL, Yoshida EM, Oger J.

Neurology. 2004 Feb 24;62(4):628-31. Review.

PMID:
14981183
13.

Multiple sclerosis: side effects of interferon beta therapy and their management.

Walther EU, Hohlfeld R.

Neurology. 1999 Nov 10;53(8):1622-7. Review.

PMID:
10563602
14.

History of modern multiple sclerosis therapy.

Lublin F.

J Neurol. 2005 Sep;252 Suppl 3:iii3-iii9. Review.

PMID:
16170498
15.

Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review.

Martinelli P, Martinelli V, Agangi A, Maruotti GM, Paladini D, Ciancia R, Rotoli B.

Am J Obstet Gynecol. 2004 Dec;191(6):2016-20. Review.

PMID:
15592285
16.

Risk of drug-induced congenital defects.

De Santis M, Straface G, Carducci B, Cavaliere AF, De Santis L, Lucchese A, Merola AM, Caruso A.

Eur J Obstet Gynecol Reprod Biol. 2004 Nov 10;117(1):10-9. Review.

PMID:
15474237
17.

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H.

Neurology. 2012 Sep 11;79(11):1130-5. doi: 10.1212/WNL.0b013e3182698c64. Epub 2012 Aug 29. Review.

18.

Fetal outcome following intrauterine amantadine exposure.

Levy M, Pastuszak A, Koren G.

Reprod Toxicol. 1991;5(1):79-81. Review.

PMID:
1807540
19.

Children exposed to chemotherapy in utero.

Gwyn K.

J Natl Cancer Inst Monogr. 2005;(34):69-71. Review.

PMID:
15784828
20.

Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy.

Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA.

Obstet Gynecol. 1991 Jul;78(1):128-35. Review.

PMID:
2047053

Supplemental Content

Support Center